(MedPage Today) — CHICAGO — SGLT2 inhibitor use was linked to reduced progression of in-situ pulmonary adenocarcinoma, an observational study showed.
Nodule growth over the median 28 months of follow-up was 62% less likely among adults prescribed…
Source link : https://www.medpagetoday.com/meetingcoverage/chest/118034
Author :
Publish date : 2025-10-20 16:49:00
Copyright for syndicated content belongs to the linked Source.
